20 stories
Real-world evidence is what tells you whether a Phase 3 result holds up in routine care. Coverage on this site has leaned on Truveta's EHR network, IQVIA, and several academic registry analyses — particularly for GLP-1 outcomes outside trial conditions.
Key reads: the Truveta EHR analysis at OMA 2026 reproducing SURMOUNT-5's tirzepatide-vs-semaglutide signal at 12 months in routine care; the Mass General Brigham JAMA study of 90,000+ HFpEF patients on semaglutide and tirzepatide; the AAN 2026 living systematic review of GLP-1 dementia incidence in 2+ million diabetics; and the Foundayo IQVIA launch tracker through retail pharmacy.
Stories here cover the registry analyses, the Truveta and IQVIA data drops, and the policy implications. See #clinical-trial for trial-side coverage.
A poster at the Obesity Medical Association annual conference (April 10-12, San Diego) showed tirzepatide achieved greater body weight reduction than semaglutide at 12 months in a real-world Truveta EHR analysis of adults with obesity without diabetes, consistent with SURMOUNT-5 clinical trial results.
Researchers analyzed 410,198 Reddit posts mentioning semaglutide or tirzepatide, finding 43.5% of 67,008 self-reported users described at least one side effect extending beyond clinical trial data.